C4 Therapeutics Business Summary

C4 Therapeutics, Inc. (CCCC) is a clinical-stage biopharmaceutical company that generates revenue primarily through high-value strategic collaborations and licensing agreements with global pharmaceutical leaders, including Roche, Biogen, Merck KGaA, and Pfizer. The company operates through its proprietary TORPEDO (Target ORiented ProtEin Degrader Optimizer) platform, which designs small-molecule medicines that harness the body’s natural ubiquitin-proteasome system to degrade disease-causing proteins. Its primary business segments are focused on oncology, with lead programs including cemsidomide (CFT7455) for multiple myeloma—currently entering Phase 2 MOMENTUM trials as of early 2026—and CFT1946 for BRAF V600X mutant solid tumors. Within the targeted protein degradation (TPD) landscape, C4 Therapeutics competes directly with Arvinas (ARVN), Kymera Therapeutics (KYMR), and Nurix Therapeutics (NRIX), positioning itself as a pioneer in developing orally bioavailable degraders for previously "undruggable" targets. The company was founded by a distinguished team of scientists and entrepreneurs, including Ken Anderson, M.D., Nathanael Gray, Ph.D., Jay Bradner, M.D., and the late Marc A. Cohen. The current leadership team is headed by President and CEO Andrew Hirsch, who brings over 25 years of biotech experience from roles at Agios and BIND Therapeutics. Other key executives include Chief Scientific Officer Paige Mahaney, Ph.D., who joined in late 2024 from Exelixis, Chief Financial Officer Kendra Adams, and Chief Medical Officer Leonard Reyno. The company’s strategic direction is further guided by Board Chairman Ron Cooper (CEO of enGene) and recent appointee Steve Hoerter (former CEO of Deciphera). Notable institutional backing includes significant positions held by Orbimed Advisors, Lynx1 Capital Management, and Bain Capital Life Sciences.